As of May 24
| -0.02 / -0.92%|
The 2 analysts offering 12-month price forecasts for Rexahn Pharmaceuticals Inc have a median target of 12.75, with a high estimate of 19.50 and a low estimate of 6.00. The median estimate represents a +490.28% increase from the last price of 2.16.
The current consensus among 2 polled investment analysts is to Buy stock in Rexahn Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.